Jan 14, 2020 / 04:00PM GMT
Tycho W. Peterson - JP Morgan Chase & Co, Research Division - Senior Analyst
Okay. We're going to go ahead and kick it off. I'm Tycho Peterson from the life science team at JPMorgan. Welcome to day 2 of the conference. I'm here to introduce Danaher. We'll do a breakout right after in the Georgian Room across the hall.
With that, let me turn it over to Tom Joyce.
Thomas P. Joyce - Danaher Corporation - CEO, President & Director
Thank you, Tycho, and thank you to the entire JPMorgan team for putting on what I know, again, will be a terrific conference. Thanks to all of you also for joining us, all of you who rose to the early bell this morning for the 8:00 session. We appreciate you all joining us.
Here are our forward-looking statements. Obviously, I will let you read those at your leisure. Maybe before we dive in, I think many of you probably saw the announcement that we put out yesterday. An announcement around a preliminary look at our fourth quarter. And as you saw from that announcement, and I'll recap here, appears that we had a
Danaher Corp at JPMorgan Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot